Is ileal orthotopic bladder substitution with an afferent tubular segment detrimental to the upper urinary tract in the long term?

PURPOSE: We determine long-term morphological changes of the upper urinary tract following ileal orthotopic bladder substitution with an afferent tubular segment without a flap-valve type antireflux procedure. MATERIALS AND METHODS: A consecutive series of long-term survivors (5 years or greater) following ileal orthotopic bladder substitution underwent regular radiological followup with excretory urography. Preoperative and postoperative renal size, parenchymal thickness, pelvicaliceal dilatation and upper urinary tract obstruction were assessed by 2 radiologists. RESULTS: A total of 76 patients with a median followup of 84 months (range 60 to 155) were evaluable. Four patients (2.6%) underwent unilateral nephroureterectomy during followup. Of the remaining 148 renoureteral units 141 (95%) revealed no significant changes in size or parenchymal thickness during followup. Renal size decreased in 6 (4%) and parenchymal thickness in 7 (5%) renoureteral units, 5 of which already had renal pathologies (dilatation, obstruction or hypoplastic kidney) preoperatively. De novo shrinkage of the parenchyma of a preoperatively normal kidney was observed in 2 (1%) renoureteral units associated with stenosis of the ureteroileal anastomosis. Of the 148 renoureteral units 14 (9%) presented with nonobstructive dilatation and 4 (3%) with complete obstruction. Preoperatively average serum creatinine level +/- SD was 98 +/- 19 micromol./l. and 10 years thereafter it was 83 +/- 27 micromol./l. CONCLUSIONS: These data suggest that unidirectional peristalsis of ureters and the afferent tubular ileal segment sufficiently protect the upper urinary tract following ileal bladder substitution up to a decade provided there are no preoperative renal pathology and no anastomotic stricture postoperatively. Additional antireflux flap-valve type implantation techniques are not required.     

Diffusion-weighted MR imaging of kidneys in healthy volunteers and patients with parenchymal diseases: initial experience

PURPOSE: To prospectively evaluate feasibility of diffusion-weighted (DW) magnetic resonance (MR) imaging in assessment of renal function in healthy volunteers and patients with various renal abnormalities and to prospectively evaluate reproducibility of DW MR imaging in volunteers. MATERIALS AND METHODS: Study protocol was approved by local ethics committee; informed consent was obtained. Eighteen healthy volunteers and 15 patients underwent transverse fat-saturated echo-planar DW MR imaging of the kidneys during normal breathing. Freehand regions of interest were delineated in the cortex and medulla of the kidneys. The following apparent diffusion coefficient (ADC) values were calculated: ADC of all b values (ADC(avg)), ADC of low b values (b = 0, 50, 100 sec/mm2; ADC(low)), and ADC of high b values (b = 500, 750, 1000 sec/mm2; ADC(high)). These values were calculated to differentiate influence of perfusion and diffusion. Reproducibility was assessed by repeating the same protocol in five randomly selected volunteers after 6 months. For statistical analysis, Student t tests were used. RESULTS: In all volunteers, ADC(avg) and ADC(high) were significantly higher in the cortex than in the medulla (P < .001). No difference between the cortex and medulla could be observed for ADC(low). Patients with renal failure had significantly lower ADC(avg) (P < .001, P = .004), ADC(low) (P = .02, P = .03), and ADC(high) (P = .02, P = .04) of cortex and medulla, respectively, than did volunteers. In the patient with pyelonephritis, all ADC values of cortex and medulla were substantially lower compared with the contralateral side, whereas patients with ureteral obstruction showed varying degrees of difference in all ADC values compared with the contralateral side. No statistically significant changes were found in the repeat study of the volunteers. CONCLUSION: DW MR imaging is feasible and reproducible in the assessment of renal function, as shown in our initial experience with a small number of patients and volunteers.     

Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats

PURPOSE: To evaluate diffusion-weighted magnetic resonance (MR) imaging for monitoring tumor response in rats after administration of combretastatin A4 phosphate. MATERIALS AND METHODS: Study protocol was approved by local ethical committee for animal care and use. Rhabdomyosarcomas implanted subcutaneously in both flanks of 17 rats were evaluated with 1.5-T MR unit by using four-channel wrist coil. Transverse T2-weighted fast spin-echo sequences, T1-weighted spin-echo sequences before and after gadodiamide administration, and transverse echo-planar diffusion-weighted MR examinations were performed before, 1 and 6 hours, and 2 and 9 days after intraperitoneal injection of vascular targeting agent (combretastatin A4 phosphate, 25 mg/kg). Apparent diffusion coefficient (ADC) was automatically calculated from diffusion-weighted MR imaging findings. These findings were compared with histopathologic results at each time point. For statistical analysis, paired Student t tests with Bonferroni correction for multiple testing were used. RESULTS: T1-weighted images before combretastatin administration showed enhancement of solid tumor tissue but not of central necrosis. At 1 and 6 hours after combretastatin injection, enhancement of solid tissue disappeared almost completely, with exception of small peripheral rim. At 2 and 9 days after combretastatin injection, enhancement progressively reappeared in tumor periphery. ADC, however, showed decrease early after combretastatin injection ([1.26 +/- 0.16]x 10(-3) mm2/sec before, [1.18 +/- 0.17]x 10(-3) mm2/sec 1 hour after [P=.0005] and [1.08 +/- 0.14]x 10(-3) mm(2)/sec 6 hours after [P=.0007] combretastatin A4 phosphate injection), histologically corresponding to vessel congestion and vascular shutdown in periphery but no necrosis. An increase of ADC ([1.79 +/- 0.13]x 10(-3) mm2/sec) (P <.0001) 2 days after combretastatin A4 phosphate injection was paralleled by progressive histologic necrosis. A significant (P <.0001) decrease in ADC 9 days after treatment ([1.41 +/- 0.15]x 10(-3) mm2/sec) corresponded to tumor regrowth. CONCLUSION: In addition to basic relaxation-weighted MR imaging and postgadolinium T1-weighted MR imaging to enable prompt detection of vascular shutdown, diffusion-weighted MR imaging was used to discriminate between nonperfused but viable and necrotic tumor tissues for early monitoring of therapeutic effects of vascular targeting agent.     

Life-threatening versus non-life-threatening manual strangulation: are there appropriate criteria for MR imaging of the neck?

The aim of the study was to determine objective radiological signs of danger to life in survivors of manual strangulation and to establish a radiological scoring system for the differentiation between life-threatening and non-life-threatening strangulation by dividing the cross section of the neck into three zones (superficial, middle and deep zone). Forensic pathologists classified 56 survivors of strangulation into life-threatening and non-life-threatening cases by history and clinical examination alone, and two blinded radiologists evaluated the MRIs of the neck. In 15 cases, strangulation was life-threatening (27%), compared with 41 cases in which strangulation was non-life-threatening (73%). The best radiological signs on MRI to differentiate between the two groups were intramuscular haemorrhage/oedema, swelling of platysma and intracutaneous bleeding (all p = 0.02) followed by subcutaneous bleeding (p = 0.034) and haemorrhagic lymph nodes (p = 0.04), all indicating life-threatening strangulation. The radiological scoring system showed a sensitivity and specificity of ≈70% for life-threatening strangulation, when at least two neck zones were affected. MRI is not only helpful in assessing the severity of strangulation, but is also an excellent documentation tool that is even admissible in court.     

Potential and limitations of diffusion-weighted magnetic resonance imaging in kidney, prostate, and bladder cancer including pelvic lymph node staging: a critical analysis of the literature

Context

Diagnosis, staging, and treatment monitoring are still suboptimal for most genitourinary tumours. Diffusion-weighted magnetic resonance imaging (DW-MRI) has already shown promise as a noninvasive imaging modality in the early detection of microstructural and functional changes in several pathologies of various organs.

Objective

To assess the potential and limitations of DW-MRI in the management of patients with kidney, prostate, and bladder cancer.

Evidence acquisition

A nonsystematic literature search using the Medline/PubMed and Embase databases for full-length papers reporting on DW-MRI for kidney, prostate, and bladder cancer was performed up to August 1, 2011. Only those articles with complete data reporting on DW-MRI applications with potential implications in solving commonly encountered clinical challenges relating to tumour detection, staging, and treatment monitoring were finally examined.

Evidence synthesis

For kidney tumours DW-MRI is a reasonable alternative to conventional cross-sectional imaging to detect and characterise focal renal lesions, especially in patients with impaired renal function. For prostate cancer, DW-MRI applied in addition to conventional T2-weighted and contrast-enhanced magnetic resonance imaging (MRI) improves tumour detection and localisation. In addition, it has shown promise for the assessment of tumour aggressiveness and for treatment monitoring during active surveillance, radiation therapy, and focal therapy. For bladder cancer, DW-MRI may improve the performance of conventional T2-weighted and contrast-enhanced MRI in the work-up of bladder cancer, helping to differentiate non-muscle-invasive from muscle-invasive tumours. For pelvic lymph nodes, initial results showed the potential to improve nodal staging of prostate and bladder cancer compared with conventional cross-sectional imaging.

Conclusions

DW-MRI holds promise to ameliorate the management of patients with kidney, prostate, and bladder cancer including pelvic lymph node staging. Current limitations include the lack of standardisation of the technique across multiple centres and the still limited expertise.     

Alternate or additional findings to stone disease on unenhanced computerized tomography for acute flank pain can impact management

PURPOSE: We evaluated the incidence and clinical relevance of alternate or additional findings on unenhanced CT in patients with acute flank pain and suspected urinary calculi. MATERIALS AND METHODS: A consecutive series of 1,500 patients underwent unenhanced CT due to acute flank pain. The absence or presence of urinary tract calculi and their localization were recorded. Alternate or additional CT findings were classified according to whether they required immediate or deferred treatment, or were of little or no clinical importance. RESULTS: Of the 1,500 patients 1,035 (69%) had urinary tract calculi, including 309 (30%) with nephrolithiasis, 377 (36%) with ureterolithiasis and 349 (34%) with the 2 conditions. Urolithiasis alone was found in 331 of these patients (32%) and additional pathological conditions were noted in 704 (68%). Of all patients 1,064 (71%) had other or additional CT findings. Of all patients 207 (14%) had nonstone related CT findings requiring immediate or deferred treatment, 464 (31%) had pathological conditions of little clinical importance and 393 (26%) had pathological conditions of no clinical relevance. CT was normal in 105 of all patients (7%). CONCLUSIONS: Unenhanced CT in patients with acute flank pain allows the accurate diagnosis of urinary stone disease and it can also provide further important information leading to emergency or deferred treatment in a substantial number of patients.     

Malignant lymphoma of the thyroid following irradiation.

A case of primary lymphocytic lymphoma of the thyroid is presented occurring in a 19-year-old woman. The young age of this patient, as well as the possibility of thymic radiation therapy as an infant, being a predisposing factor makes this case unique. The association with Hashimoto's thyroiditis has been previously reported.     

Functional evaluation of transplanted kidneys with diffusion-weighted and BOLD MR imaging: initial experience

PURPOSE: To prospectively evaluate feasibility and reproducibility of diffusion-weighted (DW) and blood oxygenation level-dependent (BOLD) magnetic resonance (MR) imaging in patients with renal allografts, as compared with these features in healthy volunteers with native kidneys. MATERIALS AND METHODS: The local ethics committee approved the study protocol; patients provided written informed consent. Fifteen patients with a renal allograft and in stable condition (nine men, six women; age range, 20-67 years) and 15 age- and sex-matched healthy volunteers underwent DW and BOLD MR imaging. Seven patients with renal allografts were examined twice to assess reproducibility of results. DW MR imaging yielded a total apparent diffusion coefficient including diffusion and microperfusion (ADC(tot)), as well as an ADC reflecting predominantly pure diffusion (ADC(D)) and the perfusion fraction. R2* of BOLD MR imaging enabled the estimation of renal oxygenation. Statistical analysis was performed, and analysis of variance was used for repeated measurements. Coefficients of variation between and within subjects were calculated to assess reproducibility. RESULTS: In patients, ADC(tot), ADC(D), and perfusion fraction were similar in the cortex and medulla. In volunteers, values in the medulla were similar to those in the cortex and medulla of patients; however, values in the cortex were higher than those in the medulla (P < .05). Medullary R2* was higher than cortical R2* in patients (12.9 sec(-1) +/- 2.1 [standard deviation] vs 11.0 sec(-1) +/- 0.6, P < .007) and volunteers (15.3 sec(-1) +/- 1.1 vs 11.5 sec(-1) +/- 0.5, P < .0001). However, medullary R2* was lower in patients than in volunteers (P < .004). Increased medullary R2* was paralleled by decreased diffusion in patients with allografts. A low coefficient of variation in the cortex and medulla within subjects was obtained for ADC(tot), ADC(D), and R2* (<5.2%), while coefficient of variation within subjects was higher for perfusion fraction (medulla, 15.1%; cortex, 8.6%). Diffusion and perfusion indexes correlated significantly with serum creatinine concentrations. CONCLUSION: DW and BOLD MR imaging are feasible and reproducible in patients with renal allografts.     

Renal and perfusion imaging at 3 T

Magnetic resonance imaging is frequently used in the workup of various renal pathologies. In daily clinical practice, these studies are mainly performed on 1.5-T magnetic resonance systems. However, the potential benefits of going to higher field strengths include higher signal-to-noise ratios, faster imaging, and better spatial resolution. As of now, few studies have been performed in the kidneys at 3 T because of the limited availability and the prevalence of signal voids, susceptibility artifacts, incomplete fat suppression, and specific absorption rate problems. In the last couple of years, however, a number of technical advances have been made to overcome these problems and allow renal imaging to be performed at 3 T. This review article aimed to provide an overview of the current clinical status of renal imaging at 3 T. We will discuss both anatomical and functional imaging of the kidneys, with some special focus on perfusion imaging.     

Diffusion-Weighted Magnetic Resonance Imaging as a Cancer Biomarker: Consensus and Recommendations

On May 3, 2008, a National Cancer Institute (NCI)-sponsored open consensus conference was held in Toronto, Ontario, Canada, during the 2008 International Society for Magnetic Resonance in Medicine Meeting. Approximately 100 experts and stakeholders summarized the current understanding of diffusion-weighted magnetic resonance imaging (DW-MRI) and reached consensus on the use of DW-MRI as a cancer imaging biomarker. DW-MRI should be tested as an imaging biomarker in the context of well-defined clinical trials, by adding DW-MRI to existing NCI-sponsored trials, particularly those with tissue sampling or survival indicators. Where possible, DW-MRI measurements should be compared with histologic indices including cellularity and tissue response. There is a need for tissue equivalent diffusivity phantoms; meanwhile, simple fluid-filled phantoms should be used. Monoexponential assessments of apparent diffusion coefficient values should use two b values (> 100 and between 500 and 1000 mm²/sec depending on the application). Free breathing with multiple acquisitions is superior to complex gating techniques. Baseline patient reproducibility studies should be part of study designs. Both region of interest and histogram analysis of apparent diffusion coefficient measurements should be obtained. Standards for measurement, analysis, and display are needed. Annotated data from validation studies (along with outcome measures) should be made publicly available. Magnetic resonance imaging vendors should be engaged in this process. The NCI should establish a task force of experts (physicists, radiologists, and oncologists) to plan, organize technical aspects, and conduct pilot trials. The American College of Radiology Imaging Network infrastructure may be suitable for these purposes. There is an extraordinary opportunity for DW-MRI to evolve into a clinically valuable imaging tool, potentially important for drug development.